Clinical Trials
13 trialsNCT07459634 2026-05-27
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
NCT07603856 2026-05-22
REVIVE
University of Chicago
Phase 2 Not yet recruiting
NCT07146230 2026-05-06
SPRINT 2
Montefiore Medical Center
Phase 2 Not yet recruiting
NCT07226063 2026-05-05
Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT07247786 2026-05-05
MIGRANT
Fundación GECP
Phase 2 Not yet recruiting
NCT06855225 2026-04-17
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Not yet recruiting
NCT07511504 2026-04-06
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
OHSU Knight Cancer Institute
Phase 2 Not yet recruiting
NCT07332351 2026-03-13
TRIFECTA
University of Washington
Phase 2 Not yet recruiting
NCT06998719 2025-05-31
ACCESS
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06650709 2024-10-23
NEOCATS
British Columbia Cancer Agency
Phase 2 Not yet recruiting
NCT06530823 2024-07-31
Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma
Eastern Hepatobiliary Surgery Hospital
Phase 2 Not yet recruiting
NCT05484583 2022-08-05
Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Phase 2 Not yet recruiting